This page shows the latest Halaven news and features for those working in and with pharma, biotech and healthcare.
Issues draft guidance recommending against second-line use in breast cancer. Eisai’s Halaven (eribulin) should not be funded by the NHS for earlier use in breast cancer patients, according to ... NICE agreed last year that Halaven should be made
NICE has given a green light to Eisai's third-line breast cancer therapy Halaven, reversing its 2012 rejection of the drug. ... Halaven is one of Eisai's key growth products, accounting for 18.6bn yen ($181m) in sales in the first half of this fiscal year
If approved, the drug will join other new therapies for STS, including Johnson &Johnson's chemotherapy agent Yondelis (trabectedin) and Eisai's Halaven (eribulin mesylate), both of which have been approved
Earlier this month, Eisai won EU approval for its Halaven (eribulin mesylate) product as a second-line treatment for adults with inoperable advanced liposarcoma, its second indication after metastatic breast cancer.
Halaven (eribulin).
While Bayer has seen reprieve the rest were not so lucky, with Eisai's breast cancer drug Halaven (eribulin), Lilly's lung cancer therapy Alimta (pemetrexed) and Roche's blockbuster
More from news
Approximately 8 fully matching, plus 18 partially matching documents found.
The company is also still very much in launch mode with its first cancer drug Halaven, which has been brought to most of the major European markets. ... Halaven's unique position as the only drug demonstrating overall survival benefit in patients who are
The approval of Halaven (eribulin, Eisai) for progressive breast cancer in the US in late 2010, and in Europe and Japan in early 2011, signalled the impact of a growing number
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Graphite is a digital agency which partners with globally respected pharma and healthcare organisations to create powerful digital experiences. We...